{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:24:57Z","timestamp":1764645897107},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1038\/sj.leu.2404511","type":"journal-article","created":{"date-parts":[[2007,2,3]],"date-time":"2007-02-03T03:46:11Z","timestamp":1170474371000},"page":"524-528","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma"],"prefix":"10.1038","volume":"21","author":[{"given":"O","family":"Weigert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Pastore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2007,2,1]]},"reference":[{"key":"BF2404511_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/0092-8674(94)90396-4","volume":"79","author":"A Ciechanover","year":"1994","unstructured":"Ciechanover A . The ubiquitin\u2013proteasome proteolytic pathway. Cell 1994; 79: 13\u201321.","journal-title":"Cell"},{"key":"BF2404511_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J . The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349\u2013360.","journal-title":"Nat Rev Cancer"},{"key":"BF2404511_CR3","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609\u20132617.","journal-title":"N Engl J Med"},{"key":"BF2404511_CR4","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BF2404511_CR5","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","volume":"20","author":"RZ Orlowski","year":"2002","unstructured":"Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420\u20134427.","journal-title":"J Clin Oncol"},{"key":"BF2404511_CR6","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1200\/JCO.2005.02.050","volume":"23","author":"OA O'Connor","year":"2005","unstructured":"O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676\u2013684.","journal-title":"J Clin Oncol"},{"key":"BF2404511_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","volume":"23","author":"A Goy","year":"2005","unstructured":"Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667\u2013675.","journal-title":"J Clin Oncol"},{"key":"BF2404511_CR8","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2005.04.6789","volume":"24","author":"SJ Strauss","year":"2006","unstructured":"Strauss SJ, Maharaj L, Hoare S, Johnson PW, Radford JA, Vinnecombe S et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006; 24: 2105\u20132112.","journal-title":"J Clin Oncol"},{"key":"BF2404511_CR9","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.1182\/blood.V91.12.4624","volume":"91","author":"I Jeremias","year":"1998","unstructured":"Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM . Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood 1998; 91: 4624\u20134631.","journal-title":"Blood"},{"key":"BF2404511_CR10","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2002-06-1768","volume":"101","author":"N Mitsiades","year":"2003","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377\u20132380.","journal-title":"Blood"},{"key":"BF2404511_CR11","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1182\/blood-2004-07-2911","volume":"105","author":"RZ Orlowski","year":"2005","unstructured":"Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058\u20133065.","journal-title":"Blood"},{"key":"BF2404511_CR12","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"G Lenz","year":"2005","unstructured":"Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984\u20131992.","journal-title":"J Clin Oncol"},{"key":"BF2404511_CR13","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064\u20133071.","journal-title":"Blood"},{"key":"BF2404511_CR14","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1432-1033.1981.tb06218.x","volume":"115","author":"TC Chou","year":"1981","unstructured":"Chou TC, Talalay P . Generalized equations for the analysis of inhibitions of Michaelis\u2013Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981; 115: 207\u2013216.","journal-title":"Eur J Biochem"},{"key":"BF2404511_CR15","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/JCO.1983.1.11.689","volume":"1","author":"H Kantarjian","year":"1983","unstructured":"Kantarjian H, Barlogie B, Plunkett W, Velasquez W, McLaughlin P, Riggs S et al. High-dose cytosine arabinoside in non-Hodgkin's lymphoma. J Clin Oncol 1983; 1: 689\u2013694.","journal-title":"J Clin Oncol"},{"key":"BF2404511_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/sj.leu.2402406","volume":"16","author":"F Lefrere","year":"2002","unstructured":"Lefrere F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587\u2013593.","journal-title":"Leukemia"},{"key":"BF2404511_CR17","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.1038\/sj.onc.1207229","volume":"22","author":"D Sampath","year":"2003","unstructured":"Sampath D, Rao VA, Plunkett W . Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22: 9063\u20139074.","journal-title":"Oncogene"},{"key":"BF2404511_CR18","doi-asserted-by":"publisher","first-page":"36611","DOI":"10.1074\/jbc.M200317200","volume":"277","author":"M MacFarlane","year":"2002","unstructured":"MacFarlane M, Merrison W, Bratton SB, Cohen GM . Proteasome-mediated degradation of Smac during apoptosis: XIAP promotes Smac ubiquitination in vitro. J Biol Chem 2002; 277: 36611\u201336616.","journal-title":"J Biol Chem"},{"key":"BF2404511_CR19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S1097-2765(04)00156-X","volume":"14","author":"XM Sun","year":"2004","unstructured":"Sun XM, Butterworth M, MacFarlane M, Dubiel W, Ciechanover A, Cohen GM . Caspase activation inhibits proteasome function during apoptosis. Mol Cell 2004; 14: 81\u201393.","journal-title":"Mol Cell"},{"key":"BF2404511_CR20","first-page":"8226","volume":"63","author":"N Martinez","year":"2003","unstructured":"Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003; 63: 8226\u20138232.","journal-title":"Cancer Res"},{"key":"BF2404511_CR21","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrc1588","volume":"5","author":"C Nakanishi","year":"2005","unstructured":"Nakanishi C, Toi M . Nuclear factor\u2013kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5: 297\u2013309.","journal-title":"Nat Rev Cancer"},{"key":"BF2404511_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4049\/jimmunol.171.1.88","volume":"171","author":"LV Pham","year":"2003","unstructured":"Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ . Inhibition of constitutive NF\u2013kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88\u201395.","journal-title":"J Immunol"},{"key":"BF2404511_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1182\/blood-2005-05-2091","volume":"107","author":"P Perez-Galan","year":"2006","unstructured":"Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D . The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006; 107: 257\u2013264.","journal-title":"Blood"},{"key":"BF2404511_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","volume":"17","author":"L Chen","year":"2005","unstructured":"Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393\u2013403.","journal-title":"Mol Cell"},{"key":"BF2404511_CR25","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1101\/gad.1304105","volume":"19","author":"SN Willis","year":"2005","unstructured":"Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005; 19: 1294\u20131305.","journal-title":"Genes Dev"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2404511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404511","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2404511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:47:53Z","timestamp":1648781273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2404511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["BF2404511"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2404511","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,1]]},"assertion":[{"value":"21 April 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2006","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2006","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2007","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}